Loading patent…
AssigneeUCL Business PLC
InventorsJane SOWDEN, Valda PAUZUOLYTE, James WAWRZYNSKI, Aara PATEL
Estimating the term…
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more of Norrie disease, age related hearing loss, diabetic maculopathy and retinopathy, retinal neovascularisation, retinal exudation, retinopathy of prematurity (ROP), Familial exudative vitreoretinopathy (FEVR), Coats disease, and other NDP-related diseases, or other beta catenin signalling-related retinal diseases.
A construct comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence.
(canceled)
4-6. (canceled)
8-9. (canceled)
12-14. (canceled)
16-18. (canceled)
A method of treating a disease, the method comprising administering a therapeutically effective amount of a construct comprising wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence to a subject in need thereof, wherein the disease is selected from the group consisting of Norrie disease, age related hearing loss, diabetic maculopathy and retinopathy, retinal neovascularisation, retinal exudation, retinopathy of prematurity (ROP), Familial exudative vitreoretinopathy (FEVR), Coats disease, and other NDP-related diseases, and other beta catenin signalling-related retinal diseases.
(canceled)
24-27. (canceled)
(canceled)
(canceled)
40-42. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.